Anuh Pharma (BOM:506260) Construction In Progress: ₹0 Mil (As of Mar. 2026)


BOM:506260 Anuh Pharma Ltd BOM:506260
86 GF Score
Price ₹78.73
GF Value ₹105.70
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Anuh Pharma Construction In Progress?

Anuh Pharma BOM:506260 -0.51% 86 Construction In Progress is ₹0 Mil as of Mar. 2026. GuruFocus rates BOM:506260 with a GF Score™ of 86/100 and a GF Value™ of ₹105.70 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Anuh Pharma's quarterly construction in progress declined from Sep. 2025 (₹5 Mil) to Dec. 2025 (₹0 Mil) but then stayed the same from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹0 Mil).

Anuh Pharma's annual construction in progress increased from Mar. 2024 (₹5 Mil) to Mar. 2025 (₹23 Mil) but then declined from Mar. 2025 (₹23 Mil) to Mar. 2026 (₹0 Mil).

Anuh Pharma Construction In Progress Historical Data

* Premium members only.

The historical data trend for Anuh Pharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anuh Pharma Construction In Progress Chart

Anuh Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 5.77 4.54 22.85 0.00

Anuh Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.85 0.00 5.41 0.00 0.00
BOM:506260
86GF Score
Anuh Pharma Ltd BOM:506260
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anuh Pharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹0 Mil mean?
Anuh Pharma (BOM:506260) has a Construction In Progress of ₹0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Anuh Pharma and its competitors.
Is Anuh Pharma's Construction In Progress too high?
Anuh Pharma's current Construction In Progress is ₹0 Mil. Overall, Anuh Pharma has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anuh Pharma's Construction In Progress compare to ZTS and UTHR?
Anuh Pharma's Construction In Progress of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Anuh Pharma and its competitors. Anuh Pharma's current Construction In Progress is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anuh Pharma stock overvalued right now?
Based on GuruFocus' analysis, Anuh Pharma (BOM:506260) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹105.70, compared to a current price of ₹78.73 — trading 25.5% below its estimated fair value. The current Construction In Progress is ₹0 Mil. Anuh Pharma's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Anuh Pharma (BOM:506260), the current Construction In Progress is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anuh Pharma (BOM:506260) Overvalued in 2026?

Based on GuruFocus' analysis, Anuh Pharma stock appears to be undervalued. The current stock price of ₹78.73 is trading 25.5% below its estimated GF Value™ of ₹105.70. GuruFocus considers Anuh Pharma to be Modestly Undervalued.

Key valuation signals for BOM:506260:

  • Construction In Progress: ₹0 Mil
  • GF Value™: ₹105.70 vs. price of ₹78.73 (25.5% below fair value)
  • GF Score™: 86/100 with 1 warning sign

No single metric tells the full story. See the BOM:506260 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anuh Pharma Business Description

Other Exchanges ANUHPHR:India
Address Dr. Annie Besant Road, North Wing, 3-A, Shiv Sagar Estate, Worli, Mumbai, MH, IND, 400 018
Anuh Pharma Ltd is engaged in the business of manufacturing and selling of Bulk drugs and chemicals. Geographically, it derives a majority of revenue from India. Its product categories include macrolides, anti-TB, anti-malarial, anti-bacterial, anti-hypertension, expectorant, quinolones, and others. The company generates revenue from the sale of Branded Prescription drugs, Over-the-Counter (OTC) drugs and Generic Prescription drugs.
86GF Score

Get the complete analysis for BOM:506260

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹78.73
Price
₹105.70
GF Value